1. Home
  2. SPHR vs FOLD Comparison

SPHR vs FOLD Comparison

Compare SPHR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sphere Entertainment Co.

SPHR

Sphere Entertainment Co.

HOLD

Current Price

$93.21

Market Cap

3.4B

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.27

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPHR
FOLD
Founded
2020
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.1B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
SPHR
FOLD
Price
$93.21
$14.27
Analyst Decision
Buy
Buy
Analyst Count
10
9
Target Price
$73.00
$27.56
AVG Volume (30 Days)
706.6K
19.8M
Earning Date
11-04-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,075,530,000.00
$598,704,000.00
Revenue This Year
$13.76
$21.49
Revenue Next Year
$9.67
$18.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.28
52 Week Low
$23.89
$5.51
52 Week High
$97.20
$14.36

Technical Indicators

Market Signals
Indicator
SPHR
FOLD
Relative Strength Index (RSI) 60.22 90.78
Support Level $90.41 $14.21
Resistance Level $95.06 $14.27
Average True Range (ATR) 3.10 0.11
MACD -0.51 0.07
Stochastic Oscillator 62.11 97.45

Price Performance

Historical Comparison
SPHR
FOLD

About SPHR Sphere Entertainment Co.

Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: